Trial · NCT01886287
P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
NCT01886287, Phase 2, Terminated, H. Lee Moffitt Cancer Center and Research Institute; results first posted 2015-01-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome. Trials, record NCT01886287. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01886287
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
- NCT number
- NCT01886287
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 2 participants, actual
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Conditions
- Neuroendocrine Carcinoma
- Interventions
- Octreotide LAR
- First posted
- 2013-06-25
- Last updated
- 2015-01-12
- Results first posted
- 2015-01-12
- Limitations and caveats
- This study was closed early due to slow accrual. There were no evaluable participants at 6 months for the planned Progression Free Survival measure.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Improved Frequency of Diarrhea | At 12 weeks | The frequencies of flushing, diarrhea, and carcinoid syndrome control rating (scale 1-5) will be measured and compared at week 0 and week 12 . These measurements will be compared using two-sided non-parametric paired Wilcoxon signed-rank. |
| Secondary | Rate of Progression Free Survival (PFS) at 6 Months | At 6 months | Progression-free survival, defined as rate of patients alive and free of progression from the date of first study treatment to the end of trial at 6 months. Progressive disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Improved Frequency of Diarrhea | At 12 weeks | Participants on study at 12 weeks | participants | NUMBER |
| SECONDARY | Rate of Progression Free Survival (PFS) at 6 Months | At 6 months | Evaluable participants on study at 6 months |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Improved Frequency of Diarrhea | Octreotide Long-acting Release (LAR) | 1 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Octreotide Long-acting Release (LAR) | 2 | |
| Overall Study | COMPLETED | Octreotide Long-acting Release (LAR) | 0 | |
| Overall Study | NOT COMPLETED | Octreotide Long-acting Release (LAR) | 2 |
Source ClinicalTrials.gov
Adverse events13
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Edema limbs | General disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Edema trunk | General disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Fatigue | General disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Blood bilirubin increased | Investigations | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Weight loss | Investigations | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Hyperkalemia | Metabolism and nutrition disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Hypokalemia | Metabolism and nutrition disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Anemia | Blood and lymphatic system disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
| other | Nausea | Gastrointestinal disorders | Octreotide Long-acting Release (LAR) | 1 | 2 | 1 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Octreotide Long-acting Release (LAR) | ||
| Total, other adverse events | Octreotide Long-acting Release (LAR) | 2 | 2 |
| Total, serious adverse events | Octreotide Long-acting Release (LAR) | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01886287
GET https://conductscience.org/api/trials/v1/NCT01886287/registered